Fatigue
Recent clinical, regulatory, research and industry developments relating to this disease.
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive Cancer.
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.
Prevalence of cancer-related fatigue based on severity: a systematic review and meta-analysis.
ERS clinical practice guidelines on treatment of sarcoidosis.
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review.
More than 50 long-term effects of COVID-19: a systematic review and meta-analysis.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 5 clinical trials expected to report results, the earliest in Q4 2026.
- 1 industry development reported.
- Q4 2026Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer Survivors
- Q4 2026Shengmai Liquid for Long COVID Fatigue: a Randomized Placebo-controlled Trial.
- Q1 2027Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NuvastaticTM in Reducing Cancer-Related Fatigue in Stage IV Colon Cancer Patients Undergoing First-Line Chemotherapy
- Q3 2027Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers
- Q4 2029Effect of Methylphenidate on Cancer-related Fatigue in Patients Treated for a Brain Tumor During Childhood or Adolescence: Protocol for a Randomized, Double-blind, Placebo-controlled Crossover Trial - the EMBRAIN Trial
Clinical MilestonesViewHide
- 2026-06-26Effect of Methylphenidate on Cancer-related Fatigue in Patients Treated for a Brain Tumor During Childhood or Adolescence: Protocol for a Randomized, Double-blind, Placebo-controlled Crossover Trial - the EMBRAIN TrialResults expected Q4 2029
- 2026-06-25Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NuvastaticTM in Reducing Cancer-Related Fatigue in Stage IV Colon Cancer Patients Undergoing First-Line ChemotherapyResults expected Q1 2027
- 2026-05-05Combination Therapy for Cancer Related Fatigue in Patients With Metastatic CancersResults expected Q3 2027
- 2026-02-09Shengmai Liquid for Long COVID Fatigue: a Randomized Placebo-controlled Trial.Results expected Q4 2026
- 2025-12-15Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer SurvivorsResults expected Q4 2026
Industry & MarketViewHide
- 2026-07-19Common antidepressant may ease long COVID’s crushing fatigueIndustry · Science Daily
- 2026-07-19IndustryCommon antidepressant may ease long COVID’s crushing fatigueIndustry · Science Daily
- 2026-06-26ClinicalEffect of Methylphenidate on Cancer-related Fatigue in Patients Treated for a Brain Tumor During Childhood or Adolescence: Protocol for a Randomized, Double-blind, Placebo-controlled Crossover Trial - the EMBRAIN TrialResults expected Q4 2029
- 2026-06-25ClinicalPhase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NuvastaticTM in Reducing Cancer-Related Fatigue in Stage IV Colon Cancer Patients Undergoing First-Line ChemotherapyResults expected Q1 2027
- 2026-06-15ClinicalPhase III Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NuvastaticTM in Reducing Cancer-Related Fatigue in Breast Cancer Patients Undergoing ChemotherapyCompleted
- 2026-05-05ClinicalCombination Therapy for Cancer Related Fatigue in Patients With Metastatic CancersResults expected Q3 2027
- 2026-03-18ClinicalEffects of Physical Activity Plus Short Course of Dexamethasone for Cancer-Related Fatigue in Advanced CancerResults posted
- 2026-02-09ClinicalShengmai Liquid for Long COVID Fatigue: a Randomized Placebo-controlled Trial.Results expected Q4 2026
- 2025-12-15ClinicalPilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer SurvivorsResults expected Q4 2026
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Neoplasms3
- Quality of Life3
- COVID-192
- Fatigue2
- Survivors2
- Antibodies, Bispecific1
- Antineoplastic Agents1
- Antineoplastic Agents, Immunological1
Leading journals6
- The New England journal of medicine6
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology3
- Military Medical Research2
- Scientific reports2
- American journal of infection control1
- Blood1
Leading researchers8
- Chen L2
- Donskov F2
- Macarulla T2
- O'Reilly EM2
- Oudard S2
- Park JO2
- Wang C2
- A'Hern R1
Affiliations (unnormalised)6
- Dana-Farber Cancer Institute3
- Memorial Sloan Kettering Cancer Center3
- University of California3
- Beth Israel Deaconess Medical Center2
- Fox Chase Cancer Center2
- Moffitt Cancer Center2
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Fatigue is a state of weariness after mental or physical exertion, marked by reduced capacity for work and a diminished ability to respond to stimuli. In the supplied literature, it is also discussed as a common symptom in long COVID and as a symptom that can complicate assessment of depression in cancer patients.
The grounding does not support a specific cause or aetiology for fatigue as a disease entity. It is mentioned in association with long COVID and with depression in cancer patients, but no single causal mechanism is established in the supplied material.
The grounding does not provide a defined biological mechanism for fatigue. The literature supplied links fatigue with anxiety and depression, and in long COVID it appears among persistent post-acute symptoms, but no mechanistic pathway is described.
The grounding does not support specific risk factors for fatigue. It is noted in the context of long COVID and in patients with cancer who are fatigued, but no general risk-factor profile is provided.
The supplied reviews describe management of fatigue mainly in the context of long COVID as part of multidisciplinary care with long-term monitoring of symptoms. No specific drug class or modality is established in the grounding for fatigue itself.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.